Mutations in voltage-gated L-type calcium channel: implications in cardiac arrhythmia

Qing Zhang\textsuperscript{a,b,}\*, Junjie Chen\textsuperscript{c,}\*, Yao Qin\textsuperscript{b}, Juejin Wang\textsuperscript{c}, and Lei Zhou\textsuperscript{b}

\textsuperscript{a}Department of Cardiology, the Second Affiliated Hospital of Nantong University, Nantong First Hospital, Nantong, Jiangsu, China; \textsuperscript{b}Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China; \textsuperscript{c}Department of Physiology, Nanjing Medical University, Nanjing, Jiangsu, China

\textbf{ABSTRACT}

The voltage-gated L-type calcium channel (LTCC) is essential for multiple cellular processes. In the heart, calcium influx through LTCC plays an important role in cardiac electrical excitation. Mutations in LTCC genes, including \textit{CACNA1C}, \textit{CACNA1D}, \textit{CACNB2} and \textit{CACNA2D}, will induce the dysfunctions of calcium channels, which result in the abnormal excitations of cardiomyocytes, and finally lead to cardiac arrhythmias. Nevertheless, the newly found mutations in LTCC and their functions are continuously being elucidated. This review summarizes recent findings on the mutations of LTCC, which are associated with long QT syndromes, Timothy syndromes, Brugada syndromes, short QT syndromes, and some other cardiac arrhythmias. Indeed, we describe the gain/loss-of-functions of these mutations in LTCC, which can give an explanation for the phenotypes of cardiac arrhythmias. Moreover, we present several challenges in the field at present, and propose some diagnostic or therapeutic approaches to these mutation-associated cardiac diseases in the future.

\textbf{ARTICLE HISTORY}

Received 12 April 2018
Revised 8 June 2018
Accepted 5 July 2018

\textbf{KEYWORDS}
Cardiac arrhythmia; L-type calcium channel; mutation

\section*{Introduction}

Cardiac arrhythmia is one of the major causes for sudden cardiac death (SCD) \cite{1,2}. Over the past decades, some arrhythmic susceptible genes, including voltage-gated L-type calcium channel (LTCC), have been identified many arrhythmia-associated mutations \cite{3–5}. LTCC is the main pathway for calcium ion influx into excitable cells in response to the membrane depolarization \cite{6,7}, which forms one part of cardiomyocyte action potentials (APs). In the heart, LTCC is a multi-subunit protein complex composed by four subunits: \textit{\alpha}_1 subunit and auxiliary \textit{\beta}, \textit{\alpha}_2\textit{\delta} and \textit{\gamma} subunits, encoded by \textit{CACNA1C} or \textit{CACNA1D}, \textit{CACNB2}, \textit{CACNA2D} and \textit{CACNG}, respectively \cite{8,9}. It has been known that the mutations in these LTCC genes induce the dysfunctions of calcium channels, which result in the abnormal excitations of cardiomyocytes, and finally lead to cardiac arrhythmias.

In this work, we summarize recent findings on the mutations in the different subunits of LTCC, which are associated with cardiac arrhythmias (Figure 1), and describe the functional roles of these mutations in channel properties (Table 1), which can shed a light in understanding of cardiac electrophysiological characteristics in these diseases.

\section*{Molecular basis of L-type calcium channel}

The pore-forming \textit{\alpha}_1 subunit, encoded by \textit{CACNA1C} or \textit{CACNA1D} gene, is the dominant voltage-gated calcium channels expressed in the working cardiomyocytes or sinoatrial nodal cells (SANCs), respectively. This \textit{\alpha}_1 subunit determines the main pharmacologic and biophysical properties of the channel \cite{8,10}, it contains four repeated homologous domains (DI-DIV), and each domain is comprised of six transmembrane segments (S1-S6) (Figure 1) \cite{10}. \textit{CaV1.2} \textit{\alpha}_{1C} (\textit{CACNA1C}) plays a critical role in the cardiovascular function. Deletion of \textit{\alpha}_{1C} subunit in mice resulted in embryonic lethality \cite{11}, and conditional knockout of smooth muscle \textit{\alpha}_{1C}
**Figure 1.** Predicted topology of Cav α1 subunit with associated β and αδ subunits shows the location of functional mutations. All mutations in α1 subunit are derived from α1C (Cav1.2), except one mutation G403_404ins is come from α1D (Cav1.3). AID = α-subunit interaction domain; BID = β-subunit interaction domain; BrS = Brugada syndrome; CCD = cardiac conduction disease; ERS = early repolarization syndrome; GK = guanylate kinase; LQTS = long QT syndrome; SH3 = Src homology 3; SQTS = short QT syndrome; SNP = single nucleotide polymorphism; TS = Timothy syndrome.

(SMAKO) lowered the arterial blood pressure in mice [12]. Recently, multiply alternative splicing events have been found in CACNA1C, which optimize the functions of Cav1.2 channel [13,14]. Moreover, alternative splicing in Cav1.2 channels make some roles in several cardiovascular diseases, including cardiac arrhythmia [15–17]. Cav1.3 α1D (CACNA1D) is highly expressed in both SANCs and cochlear inner hair cells [18–21]. Targeted deletion of α1D caused deafness, pronounced bradycardia, and nonfatal sinoatrial arrhythmia in mice [22,23].

The auxiliary β subunit modifies the gating property of α1 subunit, it can increase the calcium currents by regulating the expression of α1 subunit in the cell membrane [6,24,25]. Mechanistically, Cavβ works as a chaperone for the α subunit, and its β-interaction domain (BID) binds with the reserved α-interaction domain (AID) located at I-II loop of Cavα1 subunit, enhancing the trafficking of the channels from endoplasmic/sarcoplasmic reticulum (ER/SR) to cell membrane [24,26]. To date, 4 genes encoding β subunits (β1, 4) have been identified [27,28]; of which, Cavβ2 subunit, encoded by CACNB2 gene, is the dominant variant expressed in the heart [29], which has at least 8 distinct splice variants (β2a-h) [30,31].

The extracellular α2 and transmembrane δ subunit, linked with each other via disulfide bonds, are encoded by the gene CACNA2D [32]. The α2δ-1 subunit, encoded by CACNA2D1, is abundant in skeletal and cardiac muscles [33,34]. The α2δ-2 and α2δ-3 subunits, encoded by CACNA2D2 and CACNA2D3 respectively, express in neurons and some other tissues [33,35]. In addition, the expression of α2δ-4 subunit, encoded by CACNA2D4, is mostly copious in non-neuronal cells apart from retinal neurons [36,37]. By bioinformatics, the proteins encoded by several other genes have been identified, and they share the similar structure with α2δ subunits [38], but have not been proved to function as calcium α2δ subunits. The α2δ-1 subunit plays a vital role in hypertensive vascular Cav1.2 channel properties [39,40]. In the heart, the atrium is characterized by increased α2δ-1 protein expression as compared with the ventricle, which might lead to the Cav1.2 electrophysiological differentiation between atrial and ventricular cardiomyocytes [41]. Furthermore,
| No. | Amino acid change | Nucleotide change | Exon | Location | Mutation type | Gain/loss of function | Main effects on LTCC | Diagnosis | References |
|-----|------------------|------------------|------|----------|---------------|-----------------------|----------------------|-----------|------------|
| 1   | p.A28T           | c.82 G > A       | 2    | N-terminus | Missense | Gain | $I_{\text{Ca,L}}$ ↑, positively shift of $V_{0.5,\text{inact}}$ | LQT8 | Wemhoner et al. 2013 |
| 2   | p.A39V           | c.116 C > T      | 2    | N-terminus | Missense | Loss | $I_{\text{Ca,L}}$ ↓, LTCC trafficking ↓ | BrS3/SQT4 | Antzelevitch et al. 2007 |
| 3   | p.P381S          | c.1141 C > T     | 8A   | DI-S6 | Missense | - | N.S. | LQT8 | Fukuyama et al. 2014 |
| 4   | p.G402S          | c.1204 G > A     | 8    | DI-S6 | Missense | Gain | $V_{\text{DI}}$ ↓ | TS2 | Splawski et al. 2005 |
| 5   | p.G406R          | c.1216 G > A     | 8A   | DI-S6 | Missense | Gain | $V_{\text{DI}}$ ↓, CDI ↑ | TS1 | Splawski et al. 2004; Barrett et al. 2008 |
| 6   | p.M456I          | c.1368 G > A     | 9    | I-II loop | Missense | - | N.S. | LQT8 | Fukuyama et al. 2014 |
| 7   | p.G490R          | c.1468 G > A     | 10   | I-II loop | Missense | Loss | $I_{\text{Ca,L}}$ ↓ | BrS3/SQT4 | Antzelevitch et al. 2007 |
| 8   | p.R518C/H        | c.1552 C > T/c.1553 G > A | 12 | I-II loop | Missense | Gain | $I_{\text{Ca,L}}$ ↓, window current ↑, late current ↓ | Cardiac only TS | Boczek et al. 2015 |
| 9   | p.A582D          | c.1745 C > A     | 13   | DI-S2/S3 | Missense | Gain | $Ca_{v1.2}$ inactivation ↓ | LQT8 | Fukuyama et al. 2014 |
| 10  | p.R632R          | c.1896 G > A     | 14   | DI-S5/S6 | Splicing error | Loss | LTCC mRNA ↓ | BrS3 | Fukuyama et al. 2014 |
| 11  | p.L762F          | c.2284 C > T     | 16   | II-III loop | Missense | Gain | $Ca_{v1.2}$ inactivation ↓, window current ↑ | LQT8 | Landstrom et al. 2016 |
| 12  | p.E850del        | c.2548_2550delGAG | 19 | II-III loop | Deletion | Loss | $I_{\text{Ca,L}}$ ↓ | ERS2 | Burashnikov et al. 2010 |
| 13  | p.PB57R          | c.2570 C > G     | 19   | II-III loop | Missense | Gain | $I_{\text{Ca,L}}$ ↑, surface expression ↑ | LQT8 | Suwahn et al. 2016 |
| 14  | p.RB58H          | c.2573 G > A     | 19   | II-III loop | Missense | Gain | $Ca_{v1.2}$ inactivation ↑ | LQT8 | Fukuyama et al. 2014 |
| 15  | p.RB600G         | c.2578 C > G     | 19   | II-III loop | Missense | Gain | SSC ↑, positively shift of $V_{0.5,\text{inact}}$ | LQT8 | Wemhoner et al. 2015 |
| 16  | p.E1115K         | c.3343 G > A     | 26   | DI-S5/S6 | Missense | Loss | Single channel conductance ↓ | BrS3 | Burashnikov et al. 2010 |
| 17  | p.J1166V         | c.3496 A > G     | 28   | DI-S6 | Missense | Gain | $I_{\text{Ca,L}}$ ↑ | LQT8 | Simms. 2014 |
| 18  | p.J1166T         | c.3497 T > C     | 28   | DI-S6 | Missense | Gain | $I_{\text{Ca,L}}$ ↑, negatively shift of $V_{0.5,\text{inact}}$ | LQT8 | Wemhoner et al. 2015 |
| 19  | p.J1475M         | c.4425 C > G     | 38   | DIV-S6 | Missense | Gain | SSC ↑, Negatively shift of $V_{0.5,\text{inact}}$ | LQT8 | Wemhoner et al. 2015 |
| 20  | p.E1496K         | c.4486 G > A     | 38   | C-terminus | Missense | Gain | Negatively shift of $V_{0.5,\text{inact}}$, SSC ↑, current decay ↓ | LQT8 | Wemhoner et al. 2015 |
| 21  | p.G1783C/p.E1829_Q1833dup | c.5347 G > T/c.5485_5499dup15 | 44 | C-terminus | Missense | - | N.S. | LQT8 | Burashnikov et al. 2014 |
| 22  | p.V2014I         | c.6040 G > A     | 46   | C-terminus | Missense | Loss | $I_{\text{Ca,L}}$ ↓, negatively shift of $V_{0.5,\text{inact}}$ | SQT4 | Chen et al. 2017 |
| 23  | p.R1937P         | c.5918 G > C     | 46   | C-terminus | Missense | Loss | $I_{\text{Ca,L}}$ ↓ | BrS3 | Burashnikov et al. 2010 |

(Continued)
Table 1. (Continued).

| No. | Amino acid change | Nucleotide change | Exon | Location | Mutation type | Gain/loss of function | Main effects on LTCC | Diagnosis | References |
|-----|-------------------|-------------------|------|----------|---------------|-----------------------|----------------------|-----------|------------|
| 25  | p.N2091S          | c.6272A> G        | 47   | C-terminus | Missense       | Gain                  | $I_{Ca,L}$ ↑, negatively shift of $V_{0.5,sat}$ | -         | Sutphin et al. 2016 |
| 26  | p.K834E           | c.2500 A > G      | 19   | II-III loop | Missense       | Unknown               | LQT8                 | Boczek et al. 2013 |
| 27  | p.P857L           | c.2570 C > T      | 19   | II-III loop | Missense       | Unknown               | LQT8                 | Boczek et al. 2013 |
| 28  | p.A1473G          | c.4418 C > G      | 38   | DIV-S6    | Missense       | Unknown               | TS                   | Gillis et al. 2012 |
| 29  | p.R1880Q          | c.5639 G > A      | 44   | C-terminus | Missense       | Unknown               | BrS3                 | Burashnikov et al. 2010 |
| 30  | p.C1873Y          | c.5510 G > A      | 45   | C-terminus | Missense       | Unknown               | BrS3/SQT4            | Burashnikov et al. 2010 |
| 31  | p.R1906Q          | c.5717 G > A      | 44   | C-terminus | Missense       | Unknown               | LQT8                 | Boczek et al. 2013 |
| 32  | p.R1977Q          | c.6167 G > A      | 47   | C-terminus | Missense       | Unknown               | SQT4                 | Mazzanti et al. 2014 |
| 33  | p.D2130N          | c.6388 G > A      | 47   | C-terminus | Missense       | Unknown               | BrS3                 | Burashnikov et al. 2010 |

Mutations in CACNA1D

| No. | Amino acid change | Nucleotide change | Exon | Location | Mutation type | Gain/loss of function | Main effects on LTCC | Diagnosis | References |
|-----|-------------------|-------------------|------|----------|---------------|-----------------------|----------------------|-----------|------------|
| 1   | p.G403_404ins     | c.1028_1029 insGGG | 88   | DI-S6    | Insertion     | Loss                  | Conduction of $Ca_{V,1.3}$ ↓ | Bradycardia | Baig et al. 2011 |

Mutations in CACNB2b

| No. | Amino acid change | Nucleotide change | Exon | Location | Mutation type | Gain/loss of function | Main effects on LTCC | Diagnosis | References |
|-----|-------------------|-------------------|------|----------|---------------|-----------------------|----------------------|-----------|------------|
| 1   | p.T111            | c.32 C > T        | 2    | N-terminus | Missense       | Loss                  | Fast and slow decay ↑ | BrS4      | Cordeiro et al. 2009 |
| 2   | p.S481L           | c.1442 C > T      | 14   | C-terminus | Missense       | Loss                  | $I_{Ca,L}$ ↓        | BrS4/SQT5 | Antzelevich et al. 2007 |
| 3   | p.D601E           | c.1803 T > G      | 13b  | C-terminus | Missense       | Gain                  | Late $I_{Ca,L}$ ↑, $Ca_{V,1.2}$ inactivation ↓ | BrS4/CCD | Burashnikov et al. 2010 |
| 4   | p.A73V            | c.218 C > T       | 4    | SH3 domain | Missense       | Unknown               | Unknown               | IVF       | Burashnikov et al. 2010 |
| 5   | p.S143F           | c.428 C > T       | 5    | HOOK region | Missense       | Unknown               | Unknown               | BrS4      | Burashnikov et al. 2010 |
| 6   | p.S160T           | c.479 G > C       | 6    | HOOK region | Missense       | Unknown               | Unknown               | BrS4      | Risaard et al. 2013 |
| 7   | p.K170N           | c.510 G > T       | 7b   | HOOK region | Missense       | Unknown               | Unknown               | BrS4/CCD | Burashnikov et al. 2010 |
| 8   | p.L399F           | c.1195 C > T      | 12   | GK-like domain | Missense       | Unknown               | Unknown               | BrS4/CCD | Kanter et al. 2012 |
| 9   | p.T450I           | c.1349 C > T      | 14   | C-terminus | Missense       | Unknown               | Unknown               | BrS4      | Burashnikov et al. 2010 |
| 10  | p.D538E           | c.1614 C > A      | 13   | C-terminus | Missense       | Unknown               | Unknown               | BrS4/CCD | Kanter et al. 2012 |
| 11  | p.R571C           | c.1711 C > T      | 14   | C-terminus | Missense       | Unknown               | BrS4      | Burashnikov et al. 2010 |

Mutations in CACNA2D1

| No. | Amino acid change | Nucleotide change | Exon | Location | Mutation type | Gain/loss of function | Main effects on LTCC | Diagnosis | References |
|-----|-------------------|-------------------|------|----------|---------------|-----------------------|----------------------|-----------|------------|
| 1   | p.S755T           | c.2264 G > C      | 28   | Extracellular | Missense       | Loss                  | $I_{Ca,L}$ ↓        | SQT6      | Templin et al. 2011 |

(Continued)
| No. | Amino acid change | Nucleotide change | Exon | Location       | Mutation type | Gain/loss of function | Main effects on LTCC | Diagnosis | References                  |
|-----|-------------------|-------------------|------|----------------|---------------|------------------------|----------------------|-----------|-----------------------------|
| 2   | p.D550Y          | c.1648 G > T      | 19   | Cache domain   | Missense      | Unknown                | Unknown              | BrS9      | Burashnikov et al. 2010102  |
| 3   | p.S709N          | c.2126 G > A      | 26   | Extracellular  | Missense      | Unknown                | Unknown              | BrS9      | Burashnikov et al. 2010102  |
|     |                   |                   |      |                |               |                        |                      |           | Risgaard et al. 2013107     |
| 4   | p.Q917H          | c.2751 A > T      | 34   | Extracellular  | Missense      | Unknown                | Unknown              | BrS9      | Burashnikov et al. 2010102  |
|     |                   |                   |      |                |               |                        |                      |           | Risgaard et al. 2013107     |
| 5   | p.S956T          | c.2867 C > A      | 36   | Extracellular  | Missense      | Unknown                | Unknown              | ERS4      | Burashnikov et al. 2010102  |

BrS = Brugada syndrome; CDI = calcium-dependent inactivation; CCD = cardiac conduction disease; ERS = early repolarization syndrome; \(I_{Ca,L}\) = calcium currents of L-type channel; IVF = idiopathic ventricular fibrillation; LQT = long-QT syndrome; LTCC = L-type calcium channel; SQT = short-QT syndrome; SSC = steady-state current; TS = Timothy syndrome; \(V_{0.5,act}\) = half-activation potential; \(V_{0.5,inact}\) = half-inactivation potential; VDI = voltage-dependent inactivation.

N.S. = no significant differences vs. wild type channel.
deletion of \( \alpha_\delta \delta \delta \)-1 in mice induced the decreased Ca\( _4 \),1.2 Ca\( ^{2+} \) currents of cardiomyocytes, and also decreased the basal myocardial contractility and relaxation [42]. These observations imply the potential roles of \( \alpha_\delta \delta \delta \) subunits in cardiac arrhythmias.

The \( \gamma \) subunit, which is encoded by CACNG, has 8 isoforms and consists of 4 transmembrane domains [43]. The first \( \gamma_1 \) subunit was cloned from skeletal muscle [44,45], whereas it was not expressed in cardiac muscle [46]. The \( \gamma \) subunit distinguisingly modulates the functions by altering both activation and inactivation properties of LTCC [46]. For example, targeted disruption of \( \gamma_1 \) subunit increased the amplitude of peak calcium current in isolated myotubes [47]; whereas coexpression with \( \gamma_2 \) subunit could depolarize the activation and inactivation curve of Ca\( _4 \),1.2 channels [48]. In the heart tissue, four different \( \gamma \) subunits, \( \gamma_4 \), \( \gamma_6 \), \( \gamma_7 \), and \( \gamma_8 \), are expressed, and they all physically interact with the Ca\( _4 \),1.2 complex, which diversify the functions of Ca\( _4 \),1.2 channels [46]. To date, no evidences indicate the association of \( \gamma \) subunits and cardiac arrhythmias, thus it is of value to investigate their possible links.

Long QT and Timothy syndromes

Long QT syndrome (LQTS) is one of the most common cardiac electrophysiological diseases with an estimated prevalence of 1 in every 2,534 persons [49]. It is a typical cardiac repolarization abnormality defined by heart rate-corrected QT interval (QTc) prolongation on resting electrocardiogram (ECG) [4,50], and characterized by an increased trend for ventricular tachycardia with torsade de pointes (TdP). LQTS exists as a congenital genetic disease (cLQTS) with mutations described in different genes, which cause different types of LQTS. LQTS also can be acquired (aLQTS) by drug-intake [51] or structural heart disease [52], which may be more prevalent than cLQTS [53]. To date, 16 genes were identified to responsible for LQTS, of which, mutations in CACNA1C is accounted for long QT syndrome 8 (LQT8) [54]. Two canonical mutations in CACNA1C (p.G406R and p.G402S) are associated with a severe LQT8, namely Timothy syndrome (TS).

Timothy syndrome 1

In the 1990s, a severe syndrome which was called as the heart-hand syndrome, now known as TS or TS1, was observed in young children with significant clinical phenotypes: syndactyly, severe cardiac arrhythmia, congenital heart disease, developmental abnormalities, autism, and neurological dysfunction [55–57]. Most patients were diagnosed during neonatal period or rarely in late infancy, only two cases reported the fetal hydrops as antenatal expression of TS1 [58,59].

Slawski et al. discovered a de novo G-to-A mutation, which caused a p.G406R substitution in translational sequence at position 1216 (c. G1216A) of CACNA1C exon 8A (also known as exon 8 [60]) in all 13 individuals with TS. However, the p.G406R mutation was not identified in 180 ethnically matched controls [61], indicating that p.G406R mutation is associated with TS. This amino acid p.G406 is completely conserved in Ca\( _4 \),1C subunit of other mammalian species, and is located at the C-terminal portion of the S6 of domain I [61,62].

The inactivation of the voltage-gated calcium channel has two mechanisms: voltage-dependent inactivation (VDI) and calcium-dependent inactivation (CDI), and they play an essential role in controlling excitation-contraction coupling in cardiomyocytes [6,63–65]. Functional analysis revealed that p.G406R mutation caused the maintained inward calcium currents by impairing the two types of channel inactivation [61]. By measuring whole-cell ionic currents in transfected human embryonic kidney-293 (HEK293) cells, the p. G406R mutation slowed the VDI of Ca\( _4 \),1.2 calcium channels, while it possibly accelerated the kinetics of CDI [66]. It is known that the small glycine residues offer flexibility to allow for the I-II loop to interact with the intracellular pore of the channel [67–69], and G406 is located within a short stretch of nonhelical motif at the start of the \( \alpha_{1C} \) I-II loop [70]. Therefore, p.G406R mutation would produce a more bulky arginine residue to impede the movement of the I-II loop, leading to
the slower channel inactivation. As a result of abnormally huge calcium ion influx, the action potential duration (APD) can be prolonged. Thus, the patients’ ECG showed a prolonged QT interval leading to death from cardiac arrhythmia [66]. Interestingly, this mutant Ca_\text{v}1.2 channel function could be modulated by one anchoring protein AKAP150, elimination of which could abrogate the prolonged QT interval [71], implying AKAP150 may be a promising target for TS.

To explore the effects of the p.G406R mutation on the electrical activity and contraction of living cardiomyocytes, human skin cells from TS patients were reprogrammed to generate induced pluripotent stem cells (iPSC), and differentiated into cardiomyocytes [72]. The electrophysiological recording and calcium imaging studies revealed excessive calcium ion influx, irregular electrical activity and contraction, prolonged APs, and abnormal calcium transients in these ventricular-like cells [72,73]. Roscovitine, both an atypical LTCC blocker and a cyclin-dependent kinase inhibitor, which can enhance the VDI of Ca_\text{v}1.2, restored the electrical and calcium signaling properties of cardiomyocyte from TS patients [72–75].

Recently, TS mouse model had been generated and proved to have more arrhythmogenic events, which might be due to the increase of cytosol calcium concentration ([Ca^{2+}]_i) by sarcolemmal Ca^{2+} leak and the impairment of VDI [76]. Syndactyly or craniofacial abnormalities may also be caused by irregular Ca_\text{v}1.2^{TS} channels, because Ca_\text{v}1.2^{TS} channels affected the development of jaw and mandibular in the mouse and zebrafish models [77].

**Timothy syndrome 2**

Splawski et al. also identified two mutations, c. G1204A and c.G1216A, in exon 8 (also known as exon 8a [60]) of the CACNA1C gene, resulting in the p.G402S and p.G406R substitution, respectively [62]. Owing to that the exon 8 splice variant was found to highly express in human heart and brain, the patients who carried this mutation had a longer QT interval and more severe arrhythmia than patients with a mutation in exon 8A. Since the symptoms caused by the mutations in exon 8 were different from previous TS, this disease was named as TS2. The patients suffered from multiple arrhythmias and SCD due to the extreme prolongation of QT interval, but syndactyly might not be manifested [62,78], and these patients were more likely died of TdP and ventricular fibrillation [62].

Structurally, the glycine residue at 402 position of IS6, together with the same positions in the IIS6, IIIS6 and IVS6 segments, form the G/A/G/A motif, which is near the inner channel mouth of Ca_\text{v}1.2. These four residues interact with larger bulky residue from neighboring S6 helices to stabilize the inactivation gate [68]. In TS2, in addition to p.G406R mutation, p.G402S will also introduce a more bulky serine residue to disrupt the tightly sealing of the S6 helices, resulting in the slower deactivation [68]. Although neither heterozygous nor homozygous p.G402S transgenic mice can survive to weaning because of the high expression of exon 8 and a fatal extremely high level of calcium channels mutation, TS2-like mouse model with p.G406R had been generated by heterozygously keeping an inverted neomycin cassette in exon 8A [79], these mice could survive through adulthood due to the lowered expression of p. G406R LTCCs. The survived mice displayed the behavioral abnormalities, corresponding to the core aspects of autism spectrum disorder [79].

**Timothy syndrome with novel CACNA1C mutations**

A newborn, with healthy parents, had the similar symptoms with TS, he presented with prolonged QT interval and associated polymorphic ventricular tachycardia, dysmorphic facial features, syndactyly of the hands and feet, and joint contractures. By full gene sequencing, the patient had no p. G402S and/or p.G406R mutations, but a novel CACNA1C mutation p.A1473G had been detected in exon 38 [80]. This case expanded the molecular basis of TS, however the electrophysiological properties of this mutant channel need further investigations. Recently, another novel CACNA1C mutation p.I1166T in exon 28 was identified in a young male with diagnosed TS, and this mutation induced an overall loss of current density and a shift of activation of Ca_\text{v}1.2 channels, which lead to an increased window current [81]. However, Wemhoner et al. found this p.I1166T mutation...
could induce a leftward shift of activation curve, but an increased peak current density [82]. These different results maybe attribute to different clones of CaV1.2 subunits, or even different ratios of subunits expressed in HEK293 cells.

**Long QT syndromes without extracardiac signs**

Some LQT8, with typical long QT interval, have no extracardiac phenotypes. A novel mutation p.R518C/H in CACNA1C was just identified in patients with a complex phenotype including LQTS, hypertrophic cardiomyopathy and congenital heart defects, which was annotated as “cardiac only TS” [83]. This mutation in CaV1.2 also revealed a complex channel phenotypes, including loss of current density and inactivation in combination with increased window and late currents [83]. By whole-exome sequencing and bioinformatics/systemic biology, Boczek et al. further identified 4 novel mutations of CACNA1C in LQTS, including p.K834E, p.P857R, p.P857L, and p.R1906Q [84], 3 of which were located at the conserved proline, glutamic acid, serine and threonine rich (PEST) domain of CaVα1 II-III loop, this domain acts to proteolytic signaling through the cellular quality control system [85]. Functionally, p.P857R mutation, cosegregated with the disease within the pedigree, significantly increased calcium currents and surface membrane expression of the channel as compared with wild type (WT) CaV1.2 channel [84]. Interestingly, p.R1906Q locates one amino acid away from α1C C-terminal STIM1 (stromal-interacting molecule 1, a calcium store sensor) binding domain, which may affect STIM1-mediated CaV1.2 channel gating inhibition and channel internalization [86,87]. The identification of these CACNA1C mutations co-segregating with disease indicated that CACNA1C genetic perturbations might underscore autosomal dominant LQT8 in the absence of TS.

Additionally, five novel CACNA1C mutations (p.P381S, p.M456I, p.A582D, p.R858H, and p.G1783C) were identified in the patients with LQT8, but without typical TS phenotypes [88]. Of significance, p.R858H mutant channel had a larger $I_{Ca}$ and p.A582D mutant channel displayed a slower inactivation [88], which could partially explain the phenotype of long QT interval. By screening 540 patients with LQTS, 6 more CACNA1C mutations were identified recently, including p.A28T, p.R860G, p.I1166T, p.I1166V, p.I1475M and p.E1496K [82]. These mutations affected the different properties of channel. Briefly, p.A28T increased calcium current of L-type channel ($I_{Ca,L}$) and positively shifted steady-state inactivation (SSI), p.R860G positively shifted SSI and increased steady-state current (SSC). Both p.I1166T and p.I1166V mutations showed an increased $I_{Ca,L}$, but p.I1166T negatively shifted the steady-state activation (SSA) and channel internalization [82]. By whole-exome sequencing and bioinformatics/systemic biology, Boczek et al. further identified 4 novel mutations of CACNA1C in LQTS, including p.K834E, p.P857R, p.P857L, and p.R1906Q [84], 3 of which were located at the conserved proline, glutamic acid, serine and threonine rich (PEST) domain of CaVα1 II-III loop, this domain acts to proteolytic signaling through the cellular quality control system [85]. Functionally, p.P857R mutation, cosegregated with the disease within the pedigree, significantly increased calcium currents and surface membrane expression of the channel as compared with wild type (WT) CaV1.2 channel [84]. Interestingly, p.R1906Q locates one amino acid away from α1C C-terminal STIM1 (stromal-interacting molecule 1, a calcium store sensor) binding domain, which may affect STIM1-mediated CaV1.2 channel gating inhibition and channel internalization [86,87]. The identification of these CACNA1C mutations co-segregating with disease indicated that CACNA1C genetic perturbations might underscore autosomal dominant LQT8 in the absence of TS.

**Brugada syndromes**

Brugada syndrome (BrS), first described in 1992, is an inherited cardiac arrhythmic syndrome associated with a high risk of ventricular fibrillation without structural heart disease [91]. The ECG of the Brugada patient is characterized by right bundle branch block and ST segment elevation in precordial leads V1-V3.

The symptom of BrS typically manifests during the adulthood, but the youngest individual diagnosed with BrS is only 2 days old, while the oldest is 84 years old [92,93]. Generally, BrS is more
prevalent among male patients owing to the gender differences in the expression of cardiac transient outward potassium channel ($I_{to}$). Because of the presence of a more predominant $I_{to}$ in males compared with females, male patients are more likely to induce the loss of the AP dome and the development of phase 2 reentry and polymorphic ventricular tachycardia [94,95]. Mutations in CACNA1C, CACNB2 and CACNA2D1 can cause BrS3, BrS4 and BrS9, respectively [96,97].

**Brugada syndrome 3**

A male European descent with BrS and a shortened QTc interval showed a heterozygous mutation in exon 2 of the CACNA1C gene, which made a p.A39V substitution, near the N-terminus within a highly conserved region of the Ca$_V$1.2 [98]. In another case, a male Turkish patient with BrS and a shortened QT interval, was detected a novel heterozygous mutation in exon 10 of the CACNA1C gene was predicted to result in a p.G490R substitution in I-II loop [98]. Patch-clamp analysis in Chinese hamster ovary (CHO) cells, which were transfected with p.A39V or p.G490R mutant Ca$_V$1.2 channels, showed the current amplitude was dramatically reduced as compared with WT channels, although voltage at peak current remained unchanged [98]. These results gave an sound explanation for the shortened QT interval. Moreover, p.A39V mutant channel had a defect in trafficking of mature LTCCs, however, confocal imaging revealed the normal trafficking of p.G490R mutant Ca$_V$1.2 channels from ER to cell membrane [98]. Therefore, it is reasonable to conclude that p.G490R mutation may affect the channel open probability ($P_o$), but not cell surface expression. Interestingly, this p.A39V mutation in N-terminus also affected the calmodulin-dependent activation of Ca$_V$1.2 channel [99], but didn’t affect the surface expression of neuronal Ca$_V$1.2 channels [100], which might be involved in the mechanisms of BrS. Recently, a p.R632R in Ca$_V$1.2 $\alpha_{1C}$ due to c.G1869A mutation in exon 14 of CACNA1C gene was identified in a patient with BrS, this mutation caused an aberrant splicing, which in turn made a premature stop codon in the downstream. This type of mutation might lead to nonsense-mediated mRNA decay, which induced the loss-of-function of Ca$_V$1.2 calcium channel [101].

By screening 162 probands with BrS or BrS combined with short QT syndrome (SQTS) (BrS + SQTS), there were 7 newly identified mutations in CACNA1C, including p.E1115K, p.R1880Q, p.V2014I, p.D2130N, p.E1829_Q1833dup, p.C1873Y and p.E850del [102]. Functionally, Ca$_V$1.2 channel with p.E1115K had a reduced calcium influx. Mechanistically, this mutation strictly reduced single channel conductance, but did not change the voltage or calcium-dependent gating [103]. p.V2014I mutation in Ca$_V$1.2 channel reduced peak current density and shifted half-inactivation voltage to more negative potentials, whereas voltage at the maximum peak current remained unchanged. In another mutation, the duplication of five amino acids in exon 43 of CACNA1C (p.E1829_Q1833dup) resulted in nearly compete suppression of calcium current ($I_{Ca}$) [102]. These loss-of-function mutations may help to explain the shortening of QT interval and other features of ECG.

**Brugada syndrome 4**

In two right precordial ECG leads, the patient displayed a type I ST-segment elevation, and a novel p.T11I mutation in CACNB2b was identified. This mutant Ca$_V$1.2b had a faster fast and slow decay $I_{Ca}$ and a reduced total charge compared to WT Ca$_V$1.2b, but had almost same peak calcium current density, SSI and recovery from inactivation [104]. In 6 affected family members with BrS and a shortened QTc interval, a c.C1442T heterozygous mutation in exon 13 of the CACNB2b gene resulted in p.S481L substitution downstream of the BID of $\beta_{2b}$ subunit [98]. This mutation was not found in either 4 phenotype-negative family members or in 400 ethnically matched control alleles. The calcium current in the cells coexpressing with p.S481L Ca$_V$1.2b was dramatically smaller than WT Ca$_V$1.2b, but the surface expression was almost the same, which indicated that the p.S481L channel traffics normally [98]. Due to the fact that the mutation is located at the position nearby the BID domain binding with $\alpha_{1C}$ subunits, the mechanism of dysfunctions of calcium channel...
could be interfered by the stimulatory role of β₂ subunit on LTCC [105].

A patient with BrS, who has a p.V2014I mutation in CACNA1C, also had a p.D601E polymorphism in CACNB2b, and this polymorphism dramatically augmented the late calcium current of LTCC, which prolonged the QT interval, the modulatory effect of this single nucleotide polymorphism probably interprets the fact that QTc in this proband is not associated with SQTS [102]. Other mutations were also identified [102,106], including p.S143F and p.T450I, which were reported in the prevailing BrS-associated variants of NHLBI GO Exome Sequencing Project population [107]. However, the functions of these mutations on the Cavβ₂ subunit remain unknown.

**Brugada syndrome 9**

Human mutations in CACNA2D1 have been identified to be associated with several kinds of cardiac dysfunctions, including BrS [97]. It has been found 3 different missense mutations in CACNA2D1 (p.S709N, p.D550Y, and p.Q917H) in 3 BrS patients from a cohort made up of 205 patients with BrS [102]. Among these mutations, p.S709N and p.Q917H were also identified in Exome Sequencing Project population by Risgaard et al. [107]. Nevertheless, more works are needed to explore the possible functions of these mutations on Cav channels.

**Short QT syndromes**

The short QT syndrome (SQTS), first described in 2000 [108], was defined by an abnormally shortened QT intervals and a propensity for cardiac arrest (CA) [109,110]. SQTS has been associated with the gain-of-function mutations in 3 distinct potassium channels, KCNH2, KCNQ1 and KCNJ2, which cause SQT1, SQT2 and SQT3, respectively [111–114]. Nowadays, more evidences indicate the mutations in LTCC are also linked to SQTS. Some cardiac arrhythmias have the combined phenotypes of SQTS and BrS, since the shortened QT interval is also one of the manifestations of BrS. Thus, BrS3, caused by the mutation in CACNA1C, such as p.A39V, p.G490R, p.E1829_Q1833 duplication, and p.E850 deletion, also known as SQT4; and BrS4, caused by CACNB2 p.S481L mutation, is also known as SQT5 [98].

**Short QT syndrome 4**

One proband’s ECG showed that the QTc interval of the patient was shorter than that of healthy controls and characterized with aborted CA, and a novel CACNA1C mutation (p.R1977Q) was first identified in this SQTS patient, but the parents didn’t carry this mutation [115]. However, the roles of p.R1977Q mutation in SQTS are still unknown. Recently, a novel CACNA1C mutation p.R1937P was reported in a Chinese family of hypertrophic cardiomyopathy with early repolarization and SQTS, p.R1937P induced the loss-of-function of Cav1.2 channels, which dramatically decreased the I_Ca and hyperpolarized the SSI [116].

**Short QT syndrome 6**

A novel type of SQTS (SQT6) caused by a mutation p.S755T in the CACNA2D1 was reported in 2011 [117]. The ECG of the patient revealed a shortened QT interval. Templin et al. took advantage to analyze the functional roles of the p.S755T mutation in transfected HEK293 cells. Compared with the WT variant, p.S755T α₂δ-1 subunit extremely reduced the barium currents under the whole-cell patch clamp recording [117]. Western blotting showed that the membrane expression of α₁C subunit with mutant α₂δ-1 was similar to WT α₂δ-1 subunit, thus this mutation might only alter the open probability (P_o) of the Cav1.2 channels without modulating the membrane expression of the α₁C subunit of LTCC.

**Other cardiac arrhythmias**

**Cardiac conduction disease**

Combined mutations in CACNB2b (p.K170N/L399F) in one infant displaying BrS phenotype had a severe intraventricular conduction delay, and another case with conduction delay had identified p.D538E mutation in CACNB2b [118]. A novel polymorphism (p.D601E) was also identified in CACNB2b in the family displaying first-degree atrioventricular block, which induced the slowed
inactivation of \( \text{Ca}_V1.2 \) channels by strongly increasing the total charges [119]. Together with the mutation of \( \text{SCN}5A \) (\( \text{Na}_V1.5 \) sodium channel) in this case, the sodium current reduction can cause loss of the right ventricular epicardial AP dome absent from the slowed inactivation of calcium current and slowed conduction, whereas p. D601E polymorphism could restore the dome of APs [119]. These results suggest the gain-of-function mutation in calcium channel can rescue the loss-of-function of sodium channel mutation in the process of cardiac conduction disease without BrS. It is notable that the p.D601E polymorphism in \( \text{CACNB}2b \) was also found in the BrS, and this polymorphism could increase the late calcium current [102], indicating the multiply functions of p. D601E polymorphism.

**Idiopathic ventricular fibrillation and early repolarization syndrome**

Early repolarization has been found in patients with idiopathic ventricular fibrillation (IVF) [120,121], these IVF associated with early repolarization was also called early repolarization syndrome (ERS). Mutations in the LTCC genes, including \( \text{CACNA}1C \) and \( \text{CACNB}2b \), have been found to associate with both diseases. Burashnikov et al. reported \( \text{CACNB}2b \) p.A73V mutation was associated with IVF; and \( \text{CACNB}2b \) p.S160T or p.R571C, \( \text{CACNA}2D1 \) p.S956T, and \( \text{CACNA}1C \) p.E850 deletion had possible roles in ERS [102]. The glutamic acid at 850 position is located within the PEST domain of \( \text{Ca}_V1.2 \) loop. The mutations in the PEST domain are proved to affect the surface membrane expression of \( \text{Ca}_V1.2 \) channels [84]. Functionally, p.E850 deletion in \( \text{CACNA}1C \) is found to lead to an almost complete loss-of-function in \( I_{\text{Ca}} \) [90]. Thus, the p. E850 deletion might decrease the surface expression of LTCC presumably because of an aberrant protein degradation, which induces a dramatic reduction of \( I_{\text{Ca}} \).

**Bradycardia and sinoatrial arrhythmia**

Autorhythmicity of sinoatrial nodal pacemaker cells results from the slow auto-depolarization as a result of \( \text{Ca}_V1.3 \) calcium influx [122,123]. The inactivated \( \text{Ca}_V1.3 \) channels in mice induced strong reduction of calcium current in pacemaker cells and profoundly affected its pacemaking effect, which showed predominant sinoatrial nodal dysfunction [124]. With the inactivated \( \text{Ca}_V1.3 \) calcium currents, both sinoatrial arrhythmia and bradycardia have been observed [23,125]. A homozygous 3-bp insertion in \( \text{CACNA}1D \), inducing p. G403_404ins, was first screened from a Pakistani family with pronounced bradycardia. This p. G403_404ins, located at alternative spliced exon 8b of \( \text{Ca}_V\alpha_{1D} \), resulted in nonconducting \( \text{Ca}_V1.3 \) channels [126], which may explain the phenotype of bradycardia.

**Challenges and future diagnostic or therapeutic approaches**

Mosaicism implies that in an organism from a single zygote that is the presence of genetically distinct cell line [127]. Taken TS as an example, the p.G406R mutation in exon 8 could be detected in the oral mucosa sample but not in the blood sample of the patients’ mother [61], whereas in the case of a Chinese girl with a typical TS phenotype, the G406R mutation also expressed in her father’s oral mucosa, sperm and white blood cell [128]. Additionally, cardiac arrhythmias also have phenotypic heterogeneity. The genotype-negative or even phenotype-negative LQT8 patients had been identified several novel mutations in \( \text{CACNA}1C \) [82,88]. Hence, careful screening of parental tissue in family with incidence of congenital cardiac arrhythmias, prenatal DNA screening, and monitoring of the fetal echocardiogram are extremely significant for the congenital cardiac arrhythmia. Remarkably, whole-genome or whole-exome sequencing [129] may be necessary for the identification of potential mutations of LTCC in cardiac arrhythmias.

LTCC has many variants because of transcriptional and post-transcriptional modification, which is complicate and may be the future challenges of the field. For example, alternative splicing, one of most important mechanisms of post-transcriptional modification [130,131], generates more than 20 alternative spliced exons in \( \alpha_{1C} \) mRNA, which forms many variants of \( \alpha_{1C} \) [14,60,132]. It has been indicated the mutations
in these alternative spliced exons of LTCC can also attribute to the abnormal cardiac excitation \cite{61,62,126}. Therefore, it is noteworthy to screen the potential mutations in these alternative spliced exons of LTCC in the patients with cardiac arrhythmias.

To date, most functional studies utilized heterologous systems expressing WT or mutant calcium channels in the cultured cells, which do not fully recapitulate the phenotypes of cardiomyocytes. With the advent of iPSC, the concept of cellular reprogramming has been revolutionized, which makes producing unique human iPSC from somatic cells possible \cite{133}, then induced to specific cells. TS patient-specific iPSC-derived cardiomyocyte (iPSC-CM) carrying a missense mutation p.G406R in the CaV1.2 had been generated by traditional method or genetically encoded fluorescent indicators, which increases the inward calcium currents leading to prolonged QT interval \cite{72,134}. Recently, genetic mutations could be directly introduced into generic embryonic stem cell or non-diseased iPSCs by genome editing techniques, to produce the phenotypes of cardiac arrhythmia \cite{135}, providing an exciting approach to drug screening in the iPSC-CM-based disease model. However, iPSC techniques have several limitations when being used as a treatment strategy for the diseased heart, e.g. the stem cell-derived cardiomyocytes being cocultured with native cardiomyocytes showed an slow conduction velocity \cite{136} and inadequate excitation contraction coupling \cite{137}. Nevertheless, the iPSC approach could potentially be a powerful tool for diagnosis and prognosis of cardiac arrhythmias and provide a robust assay for developing new drugs to treat these diseases \cite{138–140}. Moreover, isogenetic control of iPSCs provides a method to reveal the pathogenic mechanism underlying the specific disease phenotype. In brief, the iPSC-based technology will play a central role in specific aspects of translational medicine \cite{141}.

It has been understood that major LTCC mutation-associated cardiac arrhythmias are attributed to the over-activities of calcium channel functions, which are due to the gain-of-function mutations in LTCC. However, the treatment of cardiac arrhythmias by calcium channel blockers meets a lot of challenges, e.g. limited range of available choices, and insufficient efficacy \cite{2,142}. Moreover, the LTCC channel blockers, which have been used in clinic for decades, have none or very little selectivity for the different LTCC variants to some extent. At the same time, these drugs induce a lot of adverse effect risks because of off-target effects. Therefore, developing highly selective calcium channel blockers targeting different variants of LTCC, or even mutant LTCC will be much attractive in the management of these mutation-associated cardiac arrhythmias.

### Conclusions

Taken together, the mutations of the LTCC genes can cause different cardiac arrhythmias, including LQTS, TS, BrS, SQTS and other cardiac arrhythmias, which are critically associated with increased risks of cardiovascular diseases, syncope and even SCD. The mechanisms how these mutations cause the distinct cardiac arrhythmias are dependent on their different roles in the channel functions (structure-function mechanisms), thus more efforts on the crystal structure analysis of the LTCC are appreciated to understand these mutation-associated cardiac arrhythmias. Nevertheless, there are some challenges in the detection, diagnosis and treatment of cardiac arrhythmias at present, the future studies will be necessary to get a better understanding of the roles of LTCC in the context of cardiac arrhythmias, which will be much valuable for the diagnosis and even management of these diseases.

### Disclosure statement

No potential conflict of interest was reported by the authors.

### Funding

This work was funded by the Natural Science Foundation of China (31371157, 81300193, 81570332), the Natural Science Foundation of Jiangsu Province (BK20171482), the Natural Science Foundation for Young Scholars of Jiangsu Province (BK20130887), the Natural Science Foundation of the Higher Education Institutions of Jiangsu Province (13KJB310002), the Science and Technology Developmental Foundation of Nanjing Medical University (2012NJMU017), the grant from Jiangsu Province’s Key Provincial Talent Program.
(ZDRCA2016019 to L.Z.), the Start-up Foundation of Nanjing Medical University (to J.W.), and a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).

**Author Contributions**

Q.Z., J.C., Y.Q. and J.W. drafted the manuscript. J.W. prepared the figures. J.W. edited the manuscript. L.Z. read and gave the comments to this work.

**References**

[1] Almanac LR. Cardiac arrhythmias and pacing. Heart. 2013;99(19):1398–1407. PMID: 23906730.
[2] Nattel S, Andrade J, Macle L, et al. New directions in cardiac arrhythmia management: present challenges and future solutions. Can J Cardiol. 2014;30(12Suppl):S420–S50. PMID: 25432137.
[3] Bokil NJ, Baisden JM, Radford DJ, et al. Molecular genetics of long QT syndrome. Mol Genet Metab. 2010;101(1):1–8. PMID: 20594883.
[4] Hedley PL, Jorgensen P, Schlamowitz S, et al. The genetic basis of long QT and short QT syndromes: a mutation update. Hum Mutat. 2009;30(11):1486–1511. PMID: 19862833.
[5] Liao P, Soong TW. CaV1.2 channelopathies: from arrhythmias to autism, bipolar disorder, and immunodeficiency. Pflugers Arch. 2010;460(2):353–359. PMID: 19916019.
[6] Catterall WA. Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol. 2000;16:521–555. PMID: 11031246.
[7] Schultz D, Mikala G, Yatani A, et al. Cloning, chromosomal localization, and functional expression of the alpha 1 subunit of the L-type voltage-dependent calcium channel from normal human heart. Proc Natl Acad Sci U S A. 1993;90(13):6228–6232. PMID: 8392192.
[8] Dolphin AC. Calcium channel diversity: multiple roles of calcium channel subunits. Curr Opin Neurobiol. 2009;19(3):237–244. PMID: 19559597.
[9] Catterall WA. Signaling complexes of voltage-gated sodium and calcium channels. Neurosci Lett. 2010;486(2):107–116. PMID: 20816922.
[10] Catterall WA. Voltage-gated calcium channels. Cold Spring Harb Perspect Biol. 2011;3(8):a003947. PMID: 21746798.
[11] Seisenberger C, Specht V, Welling A, et al. Functional embryonic cardiomyocytes after disruption of the L-type alpha1C (Cav1.2) calcium channel gene in the mouse. J Biol Chem. 2000;275(50):39193–39199. PMID: 10973973.
[12] Moosmang S, Schulla V, Welling A, et al. Dominant role of smooth muscle L-type calcium channel Cav1.2 for blood pressure regulation. EMBO J. 2003;22(22):6027–6034. PMID: 14609949.
[13] Hu Z, Lian MC, Soong TW. Alternative Splicing of L-type Cav1.2 Calcium Channels: implications in Cardiovascular Diseases. Genes. 2017;8(12):344. PMID: 29186814.
[14] Liao P, Yong TF, Lian MC, et al. Splicing for alternative structures of Cav1.2 Ca2+ channels in cardiac and smooth muscles. Cardiovasc Res. 2005;68(2):197–203. PMID: 16051206.
[15] Zhou Y, Fan J, Zhu H, et al. Aberrant splicing induced by dysregulated rbofx2 produces enhanced function of CaV1.2 calcium channel and vascular myogenic tone in hypertension. Hypertension. 2017;70(6):1183–1192. PMID: 28993448.
[16] Wang J, Li G, Yu D, et al. Characterization of CaV1.2 exon 33 heterozygous knockout mice and negative correlation between Rbfox1 and CaV1.2 exon 33 expressions in human heart failure. Channels. 2018;12(1):51–57. PMID: 28949795.
[17] Li G, Wang J, Liao P, et al. Exclusion of alternative exon 33 of CaV1.2 calcium channels in heart is proarhythmmogenic. Proc Natl Acad Sci U S A. 2017;114(21):E4288–E4295. PMID: 28490495.
[18] Zhang Q, Timofeyev V, Qiu H, et al. Expression and roles of Cav1.3 (alpha1D) L-type Ca(2+) channel in atrioventricular node automaticity. J Mol Cell Cardiol. 2011;50(1):194–202. PMID: 20951705.
[19] Brandt A, Striessnig J, Moser T. CaV1.3 channels are essential for development and presynaptic activity of cochlear inner hair cells. J Neurosci. 2003;23(34):10832–10840. PMID: 14645476.
[20] Matthes J, Yildirim L, Wietzorrek G, et al. Disturbed atrioventricular conduction and normal contractile function in isolated hearts from Cav1.3-knockout mice. Naunyn Schmiedebers Arch Pharmacol. 2004;369(6):554–562. PMID: 15146309.
[21] Green GE, Khan KM, Beisel DW, et al. Calcium channel subunits in the mouse cochlea. J Neurochem. 1996;67(1):37–45. PMID: 8667015.
[22] Dou H, Vazquez AE, Namkung Y, et al. Null mutation of alpha1D Ca2+ channel gene results in deafness but no vestibular defect in mice. J Assoc Res Otolaryngol. 2004;5(2):215–226. PMID: 15357422.
[23] Platzner J, Engel J, Schrott-Fischer A, et al. Congenital deafness and sinoatrial node dysfunction in mice lacking class D L-type Ca2+ channels. Cell. 2000;102(1):89–97. S0092-8674(00)00131-1. PMID: 10929716.
[24] Van Petegem F, Clark KA, Chatelain FC, et al. Structure of a complex between a voltage-gated calcium channel beta-subunit and an alpha-subunit domain. Nature. 2004;429(6992):671–675. PMID: 15141227.
[25] Lao QZ, Kobrinsky E, Harry JB, et al. New determinant for the CaVbeta2 subunit modulation of the CaV1.2 calcium channel. J Biol Chem. 2008;283(23):15577–15588. PMID: 18411278.
[26] Cornet V, Bichet D, Sandoz G, et al. Multiple determinants in voltage-dependent P/Q calcium channels control their retention in the endoplasmic reticulum. Eur J Neurosci. 2002;16(5):883–895. PMID: 12372025.

[27] Castellano A, Perez-Reyes E. Molecular diversity of Ca2+ channel beta subunits. Biochem Soc Trans. 1994;22(2):483–488. PMID: 7958351.

[28] Walker D, De Waard M. Subunit interaction sites in voltage-dependent Ca2+ channels: role in channel function. Trends Neurosci. 1998;21(4):148–154. S0166-2236(97)01020-9. PMID: 9554724.

[29] Perez-Reyes E, Castellano A, Kim HS, et al. Cloning and expression of a cardiac/brain beta subunit of the L-type calcium channel. J Biol Chem. 1992;267(3):1792–1797. PMID: 1370480.

[30] Takahashi SX, Mittman S, Colecraft HM. Distinctive modulatory effects of five human auxiliary beta2 subunit splice variants on L-type calcium channel gating. Biophys J. 2003;85(4):3007–3021. S0006-3495(03)70027-7. PMID: 12719232.

[31] Buraei Z, Yang J. The ss subunit of voltage-gated Ca2 + channels. Physiol Rev. 2010;90(4):1461–1506. PMID: 20959621.

[32] De Jongh KS, Warner C, Catterall WA. Subunits of purified calcium channels. Alpha 2 and delta are encoded by the same gene. J Biol Chem. 1990;265(25):14738–14741. PMID: 2168391.

[33] Klugbauer N, Lacidova L, Marais E, et al. Molecular diversity of the calcium channel alpha2delta subunit. J Neurosci. 1999;19(2):684–691. PMID: 9880589.

[34] Tuluc P, Kern G, Obermair GJ, et al. Computer modeling of siRNA knockdown effects indicates an essential role of the Ca2+ channel alpha2delta-1 subunit in cardiac excitation-contraction coupling. Proc Natl Acad Sci U S A. 2007;104(26):11091–11096. PMID: 17563358.

[35] Barclay J, Balaguer N, Mione M, et al. Ducky mouse phenotype of epilepsy and ataxia is associated with mutations in the Cacna2d2 gene and decreased calcium channel current in cerebellar Purkinje cells. J Neurosci. 2001;21(16):6095–6104. PMID: 11487633.

[36] Qin N, Yagel S, Momplaisir ML, et al. Molecular cloning and characterization of the human voltage-gated calcium channel alpha(2)delta-4 subunit. Mol Pharmacol. 2002;62(3):485–496. PMID: 12181424.

[37] Wycisk KA, Zeitz C, Feil S, et al. Mutation in the auxiliary calcium-channel subunit CACNA2D4 causes autosomal recessive cone dystrophy. Am J Hum Genet. 2006;79(5):973–977. PMID: 17033974.

[38] Whittaker CA, Hynes RO. Distribution and evolution of von Willebrand/integrin A domains: widely dispersed domains with roles in cell adhesion and elsewhere. Mol Biol Cell. 2002;13(10):3369–3387. PMID: 12388743.

[39] Bannister JP, Bulley S, Narayan D, et al. Transcriptional upregulation of alpha2delta-1 elevates arterial smooth muscle cell voltage-dependent Ca2+ channel surface expression and cerebrovascular constriction in genetic hypertension. Hypertension. 2012;60(4):1006–1015. PMID: 22949532.

[40] Bannister JP, Adelbiyot A, Zhao G, et al. Smooth muscle cell alpha2delta-1 subunits are essential for vasoregulation by CaV1.2 channels. Circ Res. 2009;105(10):948–955. PMID: 19797702.

[41] Hatano S, Yamashita T, Sekiguchi A, et al. Molecular and electrophysiological differences in the L-type Ca2 + channel of the atrium and ventricle of rat hearts. Circ J. 2006;70(5):610–614. JST.JSTAGE/circj/70.610. PMID: 16636499.

[42] Fuller-Bicer GA, Varadi G, Koch SE, et al. Targeted disruption of the voltage-dependent calcium channel alpha2/delta-1 subunit. Am J Physiol Heart Circ Physiol. 2009;297(1):H117–H24. PMID: 19429829.

[43] Bosse E, Regulla S, Biel M, et al. The cDNA and deduced amino acid sequence of the gamma subunit of the L-type calcium channel from rabbit skeletal muscle. FEBS Lett. 1990;267(1):153–156. 0014-5793(90)80312-7. PMID: 2163895.

[44] Jay SD, Ellis SB, McCue AF, et al. Primary structure of the gamma subunit of the DHPR-sensitive calcium channel from skeletal muscle. Science. 1990;248(4954):490–492. PMID: 2158672.

[45] Chen RS, Deng TC, Garcia T, et al. Calcium channel gamma subunits: a functionally diverse protein family. Cell Biochem Biophys. 2007;47(2):178–186. CBB:47:2:178. PMID: 17652770.

[46] Yang L, Katchman A, Morrow JP, et al. Cardiac L-type calcium channel (Cav1.2) associates with gamma subunits. FASEB J. 2011;25(3):928–936. PMID: 21127204.

[47] Freise D, Held B, Wissenbach U, et al. Absence of the intracellular gamma-like calcium channel subunits. FEBS Lett. 2000;470(2):189–197. PMID: 10734232.

[48] Schwartz PJ, Stramba-Badiale M, Crotti L, et al. Prevalence of the congenital long-QT syndrome. Circulation. 2009;120(18):1761–1767. PMID: 19841298.

[49] Mosc AI, Kass RS. Long QT syndrome: from channels to cardiac arrhythmias. J Clin Invest. 2005;115(8):2018–2024. PMID: 16075042.

[50] Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol. 2007;22(1):39–43. PMID: 17143043.

[51] Saffitz JE. Structural heart disease, SCN5A gene mutations, and Brugada syndrome: a complex menage a trois. Circulation. 2005;112(24):3672–3674. PMID: 16344397.

[52] Mahida S, Hogarth AJ, Cowan C, et al. Genetics of congenital and drug-induced long QT syndromes: current evidence and future research perspectives. J Interv Card Electrophysiol. 2013;37(1):9–19. PMID: 23515882.
[54] Schwartz PJ, Ackerman MJ, George AL Jr, et al. Impact of genetics on the clinical management of channelopathies. J Am Coll Cardiol. 2013;62(3):169–180. PMID: 23684683.

[55] Marks ML, Trippel DL, Keating MT. Long QT syndrome associated with syndactyly identified in females. Am J Cardiol. 1995;76(10):744–745. S0002-9149(99)80216-1. PMID: 7572644.

[56] Marks ML, Whisler SL, Clericuzio C, et al. A new form of long QT syndrome associated with syndactyly. J Am Coll Cardiol. 1995;25(1):59–64. 0735-1097 (94)00318-K. PMID: 7798527.

[57] Reichenbach H, Meister EM, Theile H. [The heart-hand syndrome. A new variant of disorders of heart conduction and syndactyly including osseous changes in hands and feet]. Kinderarztl Prax. 1992;60(2):54–56. PMID: 1318983.

[58] Corona-Rivera JR, Barrios-Prieto E, Nieto-Garcia R, et al. Unusual retrospective prenatal findings in a male newborn with Timothy syndrome type I. Eur J Med Genet. 2015;58(6–7):332–335. PMID: 25882468.

[59] La-A-Njoe SM, Wilde AA, van Erven L, et al. Syndactyly and long QT syndrome (CaV1.2 missense mutation G406R) is associated with hypertrophic cardiomyopathy. Heart Rhythm. 2005;2(12):1365–1368. PMID: 16360093.

[60] Tang ZZ, Lian MC, Lu S, et al. Transcript scanning reveals novel and extensive splice variations in human L-type voltage-gated calcium channel, Cav1.2 alpha1 subunit. J Biol Chem. 2004;279(43):44335–44343. PMID: 15299022.

[61] Splawski I, Timothy KW, Sharpe LM, et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell. 2004;119(1):19–31. PMID: 15454078.

[62] Splawski I, Timothy KW, Decher N, et al. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci U S A. 2005;102(23):8089–8096. PMID: 15863612.

[63] Stotz SC, Zamponi GW. Identification of inactivation determinants in the domain IIS6 region of high voltage-activated calcium channels. J Biol Chem. 2001;276(35):33001–33010. PMID: 11402052.

[64] Findlay I. Physiological modulation of inactivation in type Ca2+ channels: one switch. J Physiol. 2004;554 (Pt2):275–283. PMID: 12824441.

[65] Cens T, Rousset M, Leyris JP, et al. Voltage- and calcium-dependent inactivation in high voltage-gated Ca(2+) channels. Prog Biophys Mol Biol. 2006;90(1–3):104–117. PMID: 16038964.

[66] Barrett CF, Tsien RW. The Timothy syndrome mutation differentially affects voltage- and calcium-dependent inactivation of CaV1.2 L-type calcium channels. Proc Natl Acad Sci U S A. 2008;105(6):2157–2162. PMID: 18250309.

[67] Raybaud A, Dodier Y, Bissonnette P, et al. The role of the GX9GX3G motif in the gating of high voltage-activated Ca2+ channels. J Biol Chem. 2006;281 (51):39424–39436. PMID: 17038321.

[68] Depil K, Beyl S, Stary-Weininger A, et al. Timothy mutation disrupts the link between activation and inactivation in Ca(V)1.2 protein. J Biol Chem. 2011;286(36):31557–31564. PMID: 21685391.

[69] Stotz SC, Jarvis SE, Zamponi GW. Functional roles of cytoplasmic loops and pore lining transmembrane helices in the voltage-dependent inactivation of HVA calcium channels. J Physiol. 2004;554(Pt2):263–273. PMID: 12815185.

[70] Huang H, Wang J, Soong TW. Alternative exon effect on phenotype of Cav1.2 channelopathy: implications in Timothy syndrome. In: Weiss N, Koschak A, editors. Pathologies of Calcium Channels. Berlin, Heidelberg: Springer; 2014.

[71] Cheng EP, Yuan C, Navedo MF, et al. Restoration of normal L-type Ca2+ channel function during Timothy syndrome by ablation of an anchoring protein. Circ Res. 2011;109(3):255–261. PMID: 21700933.

[72] Yazawa M, Hsueh B, Jia X, et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature. 2011;471 (7337):230–234. PMID: 21307850.

[73] Pasca SP, Portmann T, Voineagu I, et al. Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome. Nat Med. 2011;17(12):1657–1662. PMID: 22120178.

[74] Yarotskyy V, Elmslie KS. Roscovitine, a cyclin-dependent kinase inhibitor, affects several gating mechanisms to inhibit cardiac L-type (Ca(V)1.2) calcium channels. Br J Pharmacol. 2007;152(3):386–395. PMID: 17700718.

[75] Yarotskyy V, Gao G, Peterson BZ, et al. The Timothy syndrome mutation of cardiac CaV1.2 (L-type) channels: multiple altered gating mechanisms and pharmacological restoration of inactivation. J Physiol. 2009;587(Pt3):551–565. PMID: 19074970.

[76] Drum BM, Dixon RE, Yuan C, et al. Cellular mechanisms of ventricular arrhythmias in a mouse model of Timothy syndrome (long QT syndrome 8). J Mol Cell Cardiol. 2014;66:63–71. PMID: 24215710.

[77] Ramachandran KV, Hennessey JA, Barnett AS, et al. Calcium influx through L-type CaV1.2 Ca2+ channels regulates mandibular development. J Clin Invest. 2013;123(4):1638–1646. PMID: 23549079.

[78] Hiippala A, Tallila J, Myllykangas S, et al. Expanding the phenotype of Timothy syndrome type 2: an adolescent with ventricular fibrillation but normal development. Am J Med Genet A. 2015;167A(3):629–634. PMID: 25691416.

[79] Bader PL, Faizi M, Kim LH, et al. Mouse model of Timothy syndrome recapitulates triad of autistic traits. Proc Natl Acad Sci U S A. 2011;108 (37):15432–15437. PMID: 21878566.

[80] Gillis J, Burashnikov E, Antzelevitch C, et al. Long QT, syndactyly, joint contractures, stroke and novel
CACNA1C mutation: expanding the spectrum of Timothy syndrome. Am J Med Genet A. 2012;158A (1):182–187. PMID: 22106044.

[81] Boczek NJ, Miller EM, Ye D, et al. Novel Timothy syndrome mutation leading to increase in CACNA1C window current. Heart Rhythm. 2015;12(1):211–219. PMID: 25260352.

[82] Wemhoner K, Friedrich C, Stallmeyer B, et al. Gain-of-function mutations in the calcium channel CACNA1C (Cav1.2) cause non-syndromic long-QT but not Timothy syndrome. J Mol Cell Cardiol. 2015;80:186–195. PMID: 25633834.

[83] Boczek NJ, Ye D, Jin F, et al. Identification and functional characterization of a novel CACNA1C-Mediated cardiac disorder characterized by prolonged QT intervals with hypertrophic cardiomyopathy, congenital heart defects, and sudden cardiac death. Circ Arrhythm Electrophysiol. 2015;8(5):1122–1132. PMID: 26253506.

[84] Boczek NJ, Best JM, Tester DJ, et al. Exome sequencing and systems biology converge to identify novel mutations in the L-type calcium channel, CACNA1C, linked to autosomal dominant long QT syndrome. Circ Cardiovasc Genet. 2013;6(3):279–289. PMID: 23677916.

[85] Rechsteiner M, Rogers SW. PEST sequences and regulation by proteolysis. Trends Biochem Sci. 1996;21(7):267–271. S0968-0004(96)10031-1. PMID: 8755249.

[86] Wang Y, Deng X, Mancarella S, et al. The calcium store sensor, STIM1, reciprocally controls Orai and CaV1.2 channels. Science. 2010;330(6000):105–109. PMID: 20929813.

[87] Park CY, Shcheglovitov A, Dolmetsch R. The CRAC channel activator STIM1 binds and inhibits L-type voltage-gated calcium channels. Science. 2010;330(6000):101–105. PMID: 20929812.

[88] Fukuyama M, Wang Q, Kato K, et al. Long QT syndrome type 8: novel CACNA1C mutations causing QT prolongation and variant phenotypes. Europace. 2014;16(12):1828–1837. PMID: 24728418.

[89] Landstrom AP, Boczek NJ, Ye D, et al. Novel long QT syndrome-associated missense mutation, L762F, in CACNA1C-encoded L-type calcium channel imparts a slower inactivation tau and increased sustained and window current. Int J Cardiol. 2016;220:290–298. PMID: 27390944.

[90] Sutphin BS, Boczek NJ, Barajas-Martinez H, et al. Molecular and functional characterization of rare CACNA1C variants in sudden unexplained death in the young. Congenit Heart Dis. 2016;11(6):683–692. PMID: 27218670.

[91] Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol. 1992;20(6):1391–1396. 0735-1097(92)90253-J. PMID: 1309182.

[92] Huang MH, Marcus FI. Idiopathic Brugada-type electrocardiographic pattern in an octogenarian. J Electrocardiol. 2004;37(2):109–111. S0022073604000147. PMID: 15127377.

[93] Antzelevitch C, Brugada P, Borggreve M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation. 2005;111(5):659–670. PMID: 15655131.

[94] Antzelevitch C. Brugada syndrome. Pacing Clin Electrophysiol. 2006;29(10):1130–1159. PMID: 17038146.

[95] Di Diego JM, Cordeiro JM, Goodrow RJ, et al. Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation. 2002;106(15):2004–2011. PMID: 12370227.

[96] Nielsen MW, Holst AG, Olesen SP, et al. The genetic component of Brugada syndrome. Front Physiol. 2013;4:179. PMID: 23874304.

[97] Brugada R, Campuzano O, Brugada P, et al. Brugada Syndrome. 1993. NBK1517 [bookaccession]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews. Seattle, WA. PMID: 20301690.

[98] Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation. 2007;115(4):442–449. PMID: 17224476.

[99] Simms BA, Souza IA, Zamponi GW. Effect of the Brugada syndrome mutation A39V on calmodulin regulation of Cav1.2 channels. Mol Brain. 2014;7:34. PMID: 24775099.

[100] Simms BA, Zamponi GW. The Brugada syndrome mutation A39V does not affect surface expression of neuronal rat Cav1.2 channels. Mol Brain. 2012;5:9. PMID: 22385640.

[101] Fukuyama M, Ohno S, Wang Q, et al. Nonsense-mediated mRNA decay due to a CACNA1C splicing mutation in a patient with Brugada syndrome. Heart Rhythm. 2014;11(4):629–634. PMID: 24321233.

[102] Burashnikov E, Pfeiffer R, Barajas-Martinez H, et al. Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. Heart Rhythm. 2010;7(12):1872–1882. PMID: 20817017.

[103] Simms B. Brugada Syndrome and Voltage-Gated Calcium Channels. In: Weiss N, Koschak A, editors. Pathologies of Calcium Channels. Berlin, Heidelberg: Springer; 2014.

[104] Cordeiro JM, Marieb M, Pfeiffer R, et al. Accelerated inactivation of the L-type calcium current due to a mutation in CACNB2b underlies Brugada syndrome. J Mol Cell Cardiol. 2009;46(5):695–703. PMID: 19358333.

[105] Hedley PL, Jorgensen P, Schlamowitz S, et al. The genetic basis of Brugada syndrome: a mutation
update. Hum Mutat. 2009;30(9):1256–1266. PMID: 19606473.

[106] Crotti L, Marcou CA, Tester DJ, et al. Spectrum and prevalence of mutations involving BrS1 through BrS12-susceptibility genes in a cohort of unrelated patients referred for Brugada syndrome genetic testing: implications for genetic testing. J Am Coll Cardiol. 2012;60(15):1410–1418. PMID: 22840528.

[107] Risgaard B, Jabbari R, Refsgaard L, et al. High prevalence of genetic variants previously associated with Brugada syndrome in new exome data. Clin Genet. 2013;84(5):489–495. PMID: 23414114.

[108] Gussak I, Brugada P, Brugada J, et al. Idiopathic short QT interval: a new clinical syndrome? Cardiology. 2000;94(2):99–102. PMID: 11173780.

[109] Bjerrregaard P, Gussak I. Short QT syndrome. Ann Noninvasive Electrocardiol. 2005;10(4):436–440. PMID: 16255754.

[110] McPate MJ, Witchel HJ, Hancox JC. Short QT syndrome. Future Cardiol. 2006;2(3):293–301. PMID: 19804087.

[111] Brugada R, Hong K, Dumaine R, et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation. 2004;109(1):30–35. PMID: 14676148.

[112] Belloq C, van Ginneken AC, Bezzaia CR, et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation. 2004;109(20):2394–2397. PMID: 15159330.

[113] Giustetto C, Schimpf R, Mazzanti A, et al. Long-term follow-up of patients with short QT syndrome. J Am Coll Cardiol. 2011;58(6):587–595. PMID: 21798421.

[114] Gollob MH, Redpath CJ, Roberts JD. The short QT syndrome: proposed diagnostic criteria. J Am Coll Cardiol. 2011;57(7):802–812. PMID: 21310316.

[115] Mazzanti A, Kanthan A, Monteforte N, et al. Novel insight into the natural history of short QT syndrome. J Am Coll Cardiol. 2014;63(13):1300–1308. PMID: 24291113.

[116] Chen Y, Barajas-Martinez H, Zhu D, et al. Novel trigenic CACNA1C/DES/MYPN mutations in a family of hypertrophic cardiomyopathy with early repolarization and short QT syndrome. J Transl Med. 2017;15(1):78. PMID: 28427417.

[117] Templin C, Ghadiri JR, Rouger JS, et al. Identification of a novel loss-of-function calcium channel gene mutation in short QT syndrome (SQTS6). Eur Heart J. 2011;32(9):1077–1088. PMID: 21830000.

[118] Kanter RJ, Pfeiffer R, Hu D, et al. Brugada-like syndrome in infancy presenting with rapid ventricular tachycardia and intraventricular conduction delay. Circulation. 2012;125(1):14–22. PMID: 22090166.

[119] Hu D, Barajas-Martinez H, Nesterenko VV, et al. Dual variation in SCN5A and CACNB2b underlies the development of cardiac conduction disease without Brugada syndrome. Pacing Clin Electrophysiol. 2010;33(3):274–285. PMID: 20025708.

[120] Aizawa Y, Tamura M, Chinushi M, et al. Idiopathic ventricular fibrillation and bradycardia-dependent intraventricular block. Am Heart J. 1993;126(6):1473–1474. PMID: 8249808.

[121] Haisaguerre M, Derval N, Sacher F, et al. Sudden cardiac arrest associated with early repolarization. N Engl J Med. 2008;358(19):2016–2023. PMID: 18463377.

[122] Gilmour RF Jr, Zipes DP. Slow inward current and cardiac arrhythmias. Am J Cardiol. 1985;55(3):89B–101B. PMID: 2857519.

[123] Verheijck EE, van Ginneken AC, Wilders R, et al. Contribution of L-type Ca2+ current to electrical activity in sinoatrial nodal myocytes of rabbits. Am J Physiol. 1999;276(3 Pt 2):H1064–H177. PMID: 10070093.

[124] Mangoni ME, Couette B, Bourinet E, et al. Functional role of L-type Cav1.3 Ca2+ channels in cardiac pacemaker activity. Proc Natl Acad Sci U S A. 2003;100(9):5543–5548. PMID: 12700358.

[125] Zhang Z, Xu Y, Song H, et al. Functional Roles of Ca(v)1.3 (alpha(1D)) calcium channel in sinoatrial nodes: insight gained using gene-targeted null mutant mice. Circ Res. 2002;90(9):981–987. PMID: 12016264.

[126] Baig SM, Koschak A, Lieb A, et al. Loss of Ca(v)1.3 (CACNA1D) function in a human channelopathy with bradycardia and congenital deafness. Nat Neurosci. 2011;14(1):77–84. PMID: 21131953.

[127] Youssoufian H, Pyeritz RE. Mechanisms and consequences of somatic mosaicism in humans. Nat Rev Genet. 2002;3(10):748–758. PMID: 12360233.

[128] Gao Y, Xue X, Hu D, et al. Inhibition of late sodium current by mexiletine: a novel pharmotherapeutic approach in timothy syndrome. Circ Arrhythm Electrophysiol. 2013;6(3):614–622. PMID: 23580742.

[129] Frohler S, Kieslich M, Langnick C, et al. Exome sequencing helped the fine diagnosis of two siblings afflicted with atypical Timothy syndrome (TS2). BMC Med Genet. 2014;15:48. PMID: 24773605.

[130] Wang ET, Sandberg R, Luo S, et al. Alternative isoform regulation in human tissue transcriptomes. Nature. 2008;456(7221):470–476. PMID: 18978772.

[131] Pan Q, Shai O, Lee LJ, et al. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet. 2008;40(12):1413–1415. PMID: 18978789.

[132] Tang ZZ, Hong X, Wang J, et al. Signature combinations of rat cardiac- and smooth-muscle Cav1.2 channels with distinct biophysical properties. Cell Calcium. 2007;41(5):417–428. PMID: 16979758.

[133] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–676. PMID: 16904174.
[134] Song L, Awari DW, Han EY, et al. Dual optical recordings for action potentials and calcium handling in induced pluripotent stem cell models of cardiac arrhythmias using genetically encoded fluorescent indicators. Stem Cells Transl Med. 2015;4(5):468–475. PMID: 25769651.

[135] Wang Y, Liang P, Lan F, et al. Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing. J Am Coll Cardiol. 2014;64(5):451–459. PMID: 25082577.

[136] Kucera JP, Prudat Y, Marcu IC, et al. Slow conduction in mixed cultured strands of primary ventricular cells and stem cell-derived cardiomyocytes. Front Cell Dev Biol. 2015;3:58. PMID: 26442264.

[137] Marcu IC, Illaste A, Heuking P, et al. Functional Characterization and Comparison of Intercellular Communication in Stem Cell-Derived Cardiomyocytes. Stem Cells. 2015;33(7):2208–2218. PMID: 25968594.

[138] Knollmann BC. Induced pluripotent stem cell-derived cardiomyocytes: boutique science or valuable arrhythmia model? Circ Res. 2013;112(6):969–976. PMID: 23569106.

[139] Terrenoire C, Wang K, Tung KW, et al. Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics. J Gen Physiol. 2013;141(1):61–72. PMID: 23277474.

[140] Sinnecker D, Dirschinger RJ, Goedel A, et al. Induced pluripotent stem cells in cardiovascular research. Rev Physiol Biochem Pharmacol. 2012;163:1–26. PMID: 22447279.

[141] Wu M, Chen G, Hu B. Induced pluripotency for translational research. Genomics Proteomics Bioinf. 2013;11(5):288–293. PMID: 24056061.

[142] Piccini JP, Zhao Y, Steinberg BA, et al. Comparative effectiveness of pharmacotherapies for prevention of atrial fibrillation following coronary artery bypass surgery. Am J Cardiol. 2013;112(7):954–960. PMID: 23850476.